
EDUCATIONAL COURSES

Mechanisms in inherited neuropathies (V. Timmerman)

• 94 genes, 1600 mutations (Timmerman Strickland & Zuchner GENES (2014))



Rossor et al. Curr Opin Neurol 2016

Mechanisms in inherited neuropathies (V. Timmerman)

- Inherited Neuropathy Variant Browser (Zuchner) : <u>http://hihg.med.miami.edu/code/http/cmt/public_html/index.html#/</u>
- Association of a mir-149 polymoprhism with onset age and severity in CMT1A (Nam et al, Neuromuscular Disorder, 2018)
- Second mutation of HSPB3 mutation in axonal CMT family
- Mutations in ATP1A1 cause dominant CMT2 (Lassuthova et al. AIHG 2018)
- COA7 mutations cause spinocerebellar ataxia with axonal neuropathy (+ cerebellar trophy ±leucopathy) (*Higuchi et al Brain 2018*)
 - Mildly elevated CPK levels
- Early onset axonal CMT due to SACS mutation
 - Pure sensorimotor axonal neuropathy without cerebellar ataxia, spastic paraplegia. Neuroimaging are similar as other sacsonopathies

Mechanisms in inherited neuropathies (V. Timmerman)

- tRNA synthetases : TARS
- HDAC6 inhibition : HDAC6 participates in neurodegeneration
- Atl3 mutations causes aberrant ER membrane tethering
- Mitochondria-associated-membranes as hubs for neurodegeneration
 - Lipid metabolism
 - Mitochondrial dynamism (MFN2)
 - Calcium metabolism (TRPV4)
 - Autophagy
- Autophagy as an emerging common pathomechanism in inherited peripheral neuropathies
 - Chaperon-Assistant-Selected-Autosystem (CASA) : BAG3...
 - Small Heat Shock Protein HSPB1

Mechanisms in inherited neuropathies (V. Timmerman)

• Potential biomarkers

- Expression of transcripts in skin biopsy
- Elevated plasma NFL conencentration
- Proteomics revealed PFN2 and GAMT as commonly downregulated proteins in different CMT2 genotypes

PFN2 decrease xith age in patients whereas it increases in healthy paptients.

Profilins (PFN2) are actin dynamics regulatros essentials for actin polymerization

GAMT belongs to creatine biosynthetic pathway

Genetic Therapies in CMT (John Svaren)

- Vector-mediated gene therapy
 - AAV
 - lentiviral : adaptaded retrovirus
- (Non viral gene delivery)
- Axonal CMT : target neurons (+ Schwann celles for neuroprotection) Demyelinating CMT : target Schwann cells
- Type of mutation : gain or loss of function mutation/ point-mutation/copy number variants...
- Therapeutic options in CMT:
 - Disease genere replacement : recessive/X-linked
 - Disease Gene Silencing : reducing overexpression or allele specific
 - Modifier-gene /genome editing: NT3, neuregulin, NGF, CNTF, GDNF...

Genetic Therapies in CMT (John Svaren)

• **CMTX** : GJB1/Connexin 32 (>400 mutations)

Lentivirus uses MPZ regulatory elements to drive Schwann cells specific expression of GJB1

Intrathecal delivery

• **ATTR** : reduce TTR production in order to minimize aggregation

RNA interference: siRNA and shRNA binduce sequence-directed mRNA degradation by the RISC complex (cf plus loin)

Antisense oliconucléotides targeting specfic sequence

• **SMA** : mutated SMN1 and non-entirely functional SMN2

Manipulate splicing in SMN2 increases the level of production of the protein

Spinraza: oligonucleotide antisense increases SMN2

AAV mediated gene repoacement intravenously

Epigenetic regulation : epigenetic repression of expression of SMN1 and 2 by a long non coding area. Using an ASO you can block interaction of this noncodant ARN and increase SMN2 expression

PLENARY SESSIONS

PRESENTATIONS

Patisiran in hATTR : APOLLO trial (Senda Ajroud-driss)

- Patisiran : rNA interfence targeting hepatic production of TTR. I/3 weeks
- Placebo controlled study
- Outcome : neuropathic score
- Adverse events : peripheral oedema, injection reaction
- Patisiran : improved health status, scales

Lysosomal and mitochondrial disorder in CMT2B (Yvette Wong)

- Mitochondria and lysosomes form dynamic membrane contact sites
- Rab7 GTP hydrolysis promotes mitochondria-lysosme contact untethering
- Rab7 GTP hydrolysis regulates mitochondrial fission marked by mitochondrialysosome contact sites
- → new pathway for mitochondria-lysosome contact involved in CMT2B, regulated by Rab7 GTP hydrolysis

PMP22 antisense oligonucleotides in rodent models of CMT1A duplication (John Svaren)

- ASO can target exonic, intronic UTR sites and can increase or decrease expression of genes
- (weekly sc in 5 weeks rodents during 8 weeks)
- PMP22 ASO treatment reverses motor deficits in the C22 moiuse modelPMP22 ASO reverses slow conducion velocities
- PMP22 ASO restores myelination in C22 mouse model
- Only a subset of deregulated gens are normalized by ASO
 Those genes may be the most sensitive biomarkers in clinical trial
 - Pou3f1 (transcription factor which expression inhibits myelination)
 - Sox4 (delays myelination)
 - C-Jun, ld2
- Schwann cell profiling in Human skin biopsies : measure PMP22 and other Schwann cell-specific genes

CMT

all-spectrin haploinsufficiency due to SPTAN1 nonsense mutations causes juvenile onset dominant hereditary motor neuropathy



Danique Beijer^{1,2}, Tine Deconinck^{1,2}, Jan De Bleecker³, Alessandro Malandrini⁴, Miren Zulaica Ijurco⁵, J. Andoni Urtizberea⁵, Peter De Jonghe^{1,2,6}, Jonathan Baets^{1,2,6}

1. Neurogenetics Group, Center for Molecular Neurology, VIB Antwerp, Beigium, 2. Laboratory of Neuromiscular Pathology, institute Born-Bunge, University of Antwerp, Beigium, 3. Department of Neurology, University resplated Green, Beigium, 4. Department of Medicine, Surgery and Neuroscience, University of Siena, Italy, 6. Neuromiscular Reference Center, Höptal Marin, AP-HP. Hendaye, France, 6. Neuromiscular Reference Center, Department of Neurology, Ant University Hospital, Belgiur

INTRODUCTION

B


distal Hereditary Motor Neuropathies (dHMN)

Most commonly features distal weakness of the extremities.

- Generally only slowly progressive towards more proximal involvement
- · Genetically and clinically heterogeneous > 90 genes are associated with IPN
- ~60-80% of patients remain undiagnosed

IDENTIFICATION OF SPTAN1 MUTATIONS

- NGS data for patients from ~60 families with hereditary motor neuropathies (HMN) is available. WES or WGS from the index patient and in some families additional affected or unaffected family members
- NGS data was generated as part of the NeurOmics consortium
- 3 separate nonsense mutations in SPTAN1 were identified in 3



CLINICAL FINDINGS

- Family A Childhood-onset gait difficulties Easily sprained ankles, frequent falls Bilateral toe-drop, heel walking
- Slow progression, walks unaided at 30

Family B

- Childhood-onset gait difficulties LL weakness and a mildly shortened
- Achilles tendon Overall slow progression • + reflexes LL
- Childhood-onset gait difficulties Family C Inability to run and frequent fails
- Bilateral Achilles tendon shortening
- rogression, walking at age 59 with can distal leg hypotrophy

HAPLOINSUFFICIENCY MECHANISM

mRNA nonsense-mediated decay

Patient lymphoblasts treated with cycloheximide



Mutant transcripts broken down by NMD pathway

Assessment of protein levels Patient lymphoblasts lysates on western blot SPTANI (280kDa)

→ Reduced αll-spectrin protein levels in patients

SPTAN1 IN dHMN VS EPILEPSY

• 22 mutations: 11 missense, 10 small duplication/deletions, 1 LoF Presumed dominant-negative mechanism Epilepsy patient fibroblasts showed spectrin aggregates Concepts patient informatic snowed spectringer
 Performed staining of dHMN patient fibroblasts

→ No all-spectrin aggregates in dHMN patients as opposed to epilepsy patients in interature¹

Future Perspectives

Frequency of SPTANI mutations in dHMN · Panel

HMN patients is plan

Plans to assess possible mild ne

me ((P7/2007-2013) under 6

SPTAN1 nonsense mutation causes a spectrum of juvenile onset hereditary motor neuropathy (Danique Beijer)

- NGS identified 3 different nonsense mutations in 3 separate families
- Childhood onset but slow progression Reflexes may be present Axonal motor neuropathy
- SPTAN1 encodes alpha-II spectrin : essential for AIS and nodes of Ranvier assembly in myelinated neurons and prevents axon degradation in larger diameter axons.
- Involved in epilepsy (dominant negative mutations)
- dHMN : haploinsufficiency mechanism